Eli Lilly and Company (NYSE:LLY) Stock Position Lifted by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. grew its holdings in Eli Lilly and Company (NYSE:LLY) by 4.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 154,106 shares of the company’s stock after purchasing an additional 7,183 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Eli Lilly and Company were worth $139,530,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Core Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the period. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC bought a new stake in shares of Eli Lilly and Company in the second quarter valued at about $36,000. Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $37,000. Finally, Redmont Wealth Advisors LLC bought a new position in Eli Lilly and Company during the first quarter valued at about $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $877.79 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The firm has a market cap of $834.26 billion, a price-to-earnings ratio of 129.28, a PEG ratio of 2.78 and a beta of 0.42. The stock has a 50-day moving average price of $896.10 and a 200 day moving average price of $843.52. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on LLY shares. Bank of America raised their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Barclays lifted their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the transaction, the insider now owns 97,299,772 shares of the company’s stock, valued at $89,059,454,309.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 423,559 shares of company stock valued at $393,136,808 over the last three months. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.